Ask AI
ProCE Banner Activity

Myeloma Masterclass on Applying the Latest Guidelines for Evidence-Based, Equitable Care: Experts Answer Your Questions

Clinical Thought

This commentary provides insights from multiple myeloma experts answering questions from an audience of healthcare professionals posed during a live satellite symposium at the American Society of Clinical Oncology annual meeting 2025 exploring the role of systemic treatment options in multiple myeloma.

Released: July 11, 2025

Expiration: July 10, 2026

Share

Provided by

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC and Sanofi.

Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC

Sanofi

Partners

Clinical Care Options, LLC

ProCE Banner

Faculty Disclosure

Primary Author

Natalie S. Callander, MD, has no relevant conflicts of interest to disclose.

Carol Ann Huff, MD: consultant/advisor/speaker: Bristol Myers Squibb, Legend Biotechnologies, Prothena, Sanofi.

Shaji Kumar, MD: consultant: AbbVie, Amgen, ArcellX, BeiGene, BD Biosciences, Bristol Myers Squibb, CARsgen, GlaxoSmithKline, Janssen, K36, Moderna, Pfizer, Regeneron, Roche/Genentech, Sanofi, Takeda; researcher (paid to institution): AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, CARsgen, GlaxoSmithKline, Gracell Bio, Janssen, Oricell, Roche/Genentech, Sanofi, Takeda, Telogenomics.